I
Ik-Kyung Jang
Researcher at Harvard University
Publications - 427
Citations - 26768
Ik-Kyung Jang is an academic researcher from Harvard University. The author has contributed to research in topics: Myocardial infarction & Intravascular ultrasound. The author has an hindex of 73, co-authored 404 publications receiving 24255 citations. Previous affiliations of Ik-Kyung Jang include Katholieke Universiteit Leuven & Hospital General Universitario Gregorio Marañón.
Papers
More filters
Journal ArticleDOI
Coronary thrombolysis with recombinant tissue-type plasminogen activator: patency rate and regional wall motion after 3 months.
Ik-Kyung Jang,Johan Vanhaecke,Hilaire De Geest,Marc Verstraete,Desire Collen,Frans Van de Werf +5 more
TL;DR: In a double-blind, placebo-controlled, randomized trial the long-term effects of intravenous administration of recombinant tissue-type plasminogen activator versus placebo were compared in relation to left ventricular function, coronary patency rate and antigenicity in 28 patients with a first myocardial infarction.
Journal ArticleDOI
Comparison of Primary Coronary Stenting to Primary Balloon Angioplasty With Stent Bailout for the Treatment of Patients With Acute Myocardial Infarction
Nasser A Mahdi,Julio Lopez,Miltiadis N Leon,Asad Pathan,Lari C. Harrell,Ik-Kyung Jang,Igor F. Palacios +6 more
TL;DR: Primary stenting results in a larger postprocedural minimal luminal diameter, a lower early and late recurrent ischemic event rate, and a lower incidence of target lesion revascularization at follow-up.
Journal ArticleDOI
The triple work-up for emergency department patients with acute chest pain: how often does it occur?
Jonathan Rogg,Jan-Walter De Neve,Calvin Huang,David F.M. Brown,Ik-Kyung Jang,Yuchiao Chang,Keith A. Marill,Blair A. Parry,Udo Hoffmann,John T. Nagurney +9 more
TL;DR: Although the "triple work-up" evaluation for ACS, PE, and AD is relatively uncommon, a significant number of ED patients who are evaluated for at least one of these three major chest pain syndromes receive simultaneous testing for one of the others.
Journal ArticleDOI
A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: Evaluation of MCC-135 for left ventricular salvage in acute myocardial infarction (EVOLVE).
Ik-Kyung Jang,Neil J. Weissman,Michael H. Picard,Michael R. Zile,Veronica Pettigrew,Steven Shen,Jun Tatsuno,Mark G. Hibberd,Dan Tzivoni,Frans J. Th. Wackers +9 more
TL;DR: There were no significant benefits of MCC-135 on preservation of LVEF and reduction of infarct size on day 5 in patients with STEMI undergoing primary PCI, and the drug appeared to be safe and well tolerated.
Journal ArticleDOI
Spatial heterogeneity of neoatherosclerosis and its relationship with neovascularization and adjacent plaque characteristics: Optical coherence tomography study
Jinwei Tian,Jinwei Tian,Xuefeng Ren,Shiro Uemura,Harold L. Dauerman,Abhiram Prasad,Catalin Toma,Haibo Jia,Haibo Jia,Farhad Abtahian,Rocco Vergallo,Sining Hu,Sining Hu,Iris McNulty,Hang Lee,Stephen M. S. Lee,Bo Yu,Ik-Kyung Jang +17 more
TL;DR: Neoatherosclerosis was associated with NV and adjacent lipid plaque, suggesting potential interrelationship between development of NA andNV and adjacent plaque characteristics.